Trials / Active Not Recruiting
Active Not RecruitingNCT03519230
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With BGB-290 Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 224 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy, safety and tolerability of maintenance therapy with BGB-290(Pamiparib) versus placebo in Chinese participants with recurrent ovarian cancer who achieved a complete response (CR) or partial response (PR) after platinum-based chemotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pamiparib capsule | 60 mg twice daily (BID), orally (per os-PO) |
| DRUG | Placebo capsule | 60mg BID, PO |
Timeline
- Start date
- 2018-05-14
- Primary completion
- 2025-12-01
- Completion
- 2027-01-30
- First posted
- 2018-05-08
- Last updated
- 2026-03-16
Locations
28 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03519230. Inclusion in this directory is not an endorsement.